Question 1

What are the expected benefits of HDR brachytherapy for my specific case?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I be aware of during and after treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

Question 3

How does HDR brachytherapy compare to other treatment options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment process look like, and how long will it take?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks associated with the procedures involved in HDR brachytherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during and after the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer clinical trial (NCT02077335). Contact the study team or your healthcare provider for specific answers.

What this study is about